Email
IZ Express #1,788: Respiratory virus vaccine coverage, VBI bankruptcy-related PreHevbrio recall, translated resources, and more
| From | Immunize.org <[email protected]> |
| Subject | IZ Express #1,788: Respiratory virus vaccine coverage, VBI bankruptcy-related PreHevbrio recall, translated resources, and more |
| Date | November 27, 2024 11:16 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,788: November 27, 2024
Top Stories
* “Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults—United States, Fall 2024” published in MMWR
* “Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents—National Healthcare Safety Network, United States, November 2024” published in MMWR
* VBI Vaccines recalls remaining doses of PreHevbrio, its HepB vaccine, as part of business closure, not due to vaccine safety or effectiveness
* CDC issues Health Alert Network (HAN) Health Advisory: “First Case of Clade I Mpox Diagnosed in the United States”
* National Influenza Vaccination Week is December 2–6. Encourage vaccination using CDC’s digital media toolkit.
* Immunize.org offers new Spanish translation of the clinical resource, “Record of Vaccine Declination”
* Immunize.org updates Spanish translation of the patient handout, "You're 16 . . . We Recommend These Vaccines for You!"
* Immunize.org updates seven translations of its popular patient handout promoting vaccinations for adults
* Immunize.org updates its clinical resource, “Hepatitis A, B, and C: Learn the Differences”
* Influenza activity gradually increasing; we are thankful for those who vaccinated our friends and families this holiday season
* Immunize.org’s Hepatitis B Birth Dose Honor Roll recognizes 586 institutions, including one new honoree
* "How Effective Is Tdap Vaccination During Pregnancy at Protecting Newborns from Pertussis?” Watch the 2-minute answer, part of the Ask the Experts Video Series on YouTube.
* Vaccines in the news
Immunize.org Website and Clinical Resources
* Recap: Immunize.org issues updated “Standing Orders for Administering Pneumococcal Vaccines to Adults” incorporating ACIP recommendation for routine vaccination starting at age 50 years
* Recap: Immunize.org updates its “Ask the Experts” web page on pneumococcal vaccines to reflect new adult recommendations
* Recap: Immunize.org updates two “Questions and Answers” resources, one for polio and one for rabies
* Recap: Immunize.org updates content in three clinical resources
Vaccine Information Statements
* Recap: Immunize.org updates Spanish translations of four popular VISs
Notable Publications
* CDC reports on pediatrician and obstetrician attitudes, practices, and challenges with administering nirsevimab and RSV vaccine
Upcoming Events
* Virtual: Questions about our website? Register for the next Immunize.org Website Office Hours on December 4 at 4:00 p.m. (ET) or December 5 at 12:00 p.m. (ET). Previously recorded sessions available online.
* Opportunity for students in grades 6 through 12: 2025 Dr. Maurice R. Hilleman Essay Contest is open for submissions
------------------------------------------------------------
Top Stories
------------------------------------------------------------
“Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults—United States, Fall 2024” published in MMWR
CDC published Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults—United States, Fall 2024 ([link removed]) on November 21 in MMWR. Most adults still need to be vaccinated against important respiratory viruses this season. A portion of the summary appears below.
The Advisory Committee on Immunization Practices recommends that all persons aged ≥6 months, including adults aged ≥18 years, receive annual influenza and COVID-19 vaccines, and that all adults aged ≥75 years and those aged 60–74 years at increased risk for severe respiratory syncytial virus (RSV) disease receive 1 dose of RSV vaccine. . . .
By November 9, 2024, an estimated 34.7% and 17.9% of adults aged ≥18 years had received influenza and COVID-19 vaccines, respectively, for the 2024–25 season; 39.7% of adults aged ≥75 years and 31.6% of adults aged 60–74 years at increased risk for severe RSV disease had ever received RSV vaccine. Many unvaccinated adults reported intent to get vaccinated. . . .
Health care providers and immunization programs still have time to expand outreach and promote vaccination activities to increase coverage in preparation for the height of the respiratory virus season.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
“Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents—National Healthcare Safety Network, United States, November 2024” published in MMWR
CDC published Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents—National Healthcare Safety Network, United States, November 2024 ([link removed]) on November 21 in MMWR. A portion of the summary appears below.
Nursing home residents are at increased risk for severe COVID-19, influenza, and respiratory syncytial virus (RSV) illness. Vaccination reduces risk for severe outcomes from these vaccine-preventable respiratory diseases. . . .
As of November 10, 2024, 30% of nursing home residents had received a 2024–2025 COVID-19 vaccine. Among residents at nursing home facilities that elected to report vaccination against influenza (59% of facilities) and RSV (52% of facilities), 58% had received influenza vaccination, and only 18% had received RSV vaccination. . . .
Addressing low vaccination coverage against COVID-19, influenza, and RSV is a priority to protect residents susceptible to severe outcomes of respiratory illnesses.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
VBI Vaccines recalls remaining doses of PreHevbrio, its HepB vaccine, as part of business closure, not due to vaccine safety or effectiveness
VBI Vaccines, the manufacturer of the PreHevbrio brand of HepB vaccine, declared bankruptcy and is ending business operations. PreHevbrio is no longer being distributed. Customers with the product are asked to destroy or return remaining doses. The recall is not related to vaccine safety or quality. All properly administered doses of PreHevbrio are valid HepB vaccinations and do not need to be repeated.
If you have PreHevbrio or have questions about it, visit www.prehevbrio.com for additional information and guidance.
Adults with an incomplete PreHevbrio vaccination series may complete their series with any of the three FDA-licensed HepB vaccines (Heplisav-B, Dynavax; Engerix-B, GSK; Recombivax-HB, Merck). For a guide to completing a mixed-product vaccination series, see the table in the following Ask the Experts HepB question:
* Can You Show the Options of How to Complete Adult Hepatitis B Vaccination with Different Vaccine Products? ([link removed])
Related Links
* VBI Vaccines: PreHevbrio Vaccine ([link removed]) web page
* Immunize.org: Ask the Experts: Hepatitis B ([link removed]) web page
------------------------------------------------------------
CDC issues Health Alert Network (HAN) Health Advisory: “First Case of Clade I Mpox Diagnosed in the United States”
On November 18, CDC issued a Health Alert Network (HAN) ([link removed]) Health Advisory: First Case of Clade I Mpox Diagnosed in the United States ([link removed]). A portion of the summary of the HAN appears below.
On November 15, 2024, the California Department of Public Health (CDPH) confirmed the first reported case of clade I mpox in the United States. [Clade IIb, a generally milder strain of mpox, was introduced to the United States in 2022 and is the cause of U.S. outbreaks since that time.] This individual had recently traveled to areas experiencing clade I monkeypox virus (MPXV) transmission and sought medical care for mpox symptoms in the United States. Consistent with other recent clade I mpox cases, the patient has relatively mild illness and is recovering. CDC and the local and state health departments are investigating potential contacts; no additional cases in the United States have been detected as of November 18, 2024. The risk of clade I mpox to the public in the United States remains low.
Related Links
* CDC: Interim Clinical Considerations for Use of Jynneos Vaccine for Mpox Prevention in the United States ([link removed])
* Immunize.org: Vaccines A–Z: Mpox ([link removed]) main page
* Immunize.org: Mpox VIS ([link removed]) and available translations
------------------------------------------------------------
National Influenza Vaccination Week is December 2–6. Encourage vaccination using CDC’s digital media toolkit.
The majority of Americans are not prepared for the coming seasonal influenza epidemic. National Influenza Vaccination Week ([link removed]) (NIVW), observed December 2–6 this year, highlights the value of influenza vaccination in December and beyond. First organized by CDC in 2005, NIVW is a great time to post and share reminder messages and vaccinate all those who are not yet protected. Get the word out using CDC's 2024 NIVW Digital Media Toolkit ([link removed]), which include the following assets.
* Sample Newsletter Text: include CDC’s sample text in your email newsletter or other communications
* Patient Reminder Messages: remind patients by sharing key messages through your patient portal or other reminders
* Social Media Messages: use CDC’s suggested X, Facebook, and Instagram graphics and text to spread the word; schedule content to remind your networks about the importance of flu vaccination throughout the week
Use #FightFlu and #NIVW to join the conversation all week.
------------------------------------------------------------
Immunize.org offers new Spanish translation of the clinical resource, “Record of Vaccine Declination”
At the request of a vaccinating nurse at a recent conference, Immunize.org now offers a Spanish translation ([link removed]) of its valuable clinical resource, Record of Vaccine Declination ([link removed]). This form helps vaccination providers document that parents declined vaccination after receiving information about the potential consequences of their choices. Many providers use it to help parents understand that vaccine refusal is an active decision to accept the risks of remaining vulnerable to a preventable disease.
The translation incorporates RSV preventive antibody (nirsevimab, Beyfortus, Sanofi) among immunizing products that parents could decline. The reverse side provides information about the value of documenting declination in the medical record, along with useful references. This section now provides more recent examples of the consequences of not vaccinating, as well as links to resources from the American Academy of Pediatrics and other organizations.
* Record of Vaccine Declination ([link removed]) (view in English ([link removed]) )
Related Links
* Immunize.org: Clinical Resources: Documenting Vaccination ([link removed]) main page
* Immunize.org: Translations ([link removed]) main page, where you can locate available translations of clinical resources and VISs, organized by language
------------------------------------------------------------
Immunize.org updates Spanish translation of the patient handout, "You're 16 . . . We Recommend These Vaccines for You!"
Immunize.org recently updated the Spanish translation ([link removed]) of its patient handout, coproduced with the Society for Adolescent Health and Medicine, You're 16 . . . We Recommend These Vaccines for You! ([link removed]) The handout includes COVID-19 as a routinely recommended vaccine and a footnote about RSV vaccine during pregnancy. Vaccines normally administered to preteens (which may be needed by teens who are not up to date) are now grouped in a separate table.
Related Links
* Immunize.org: Translations ([link removed]) main page, where you can locate available translations of clinical resources and VISs, organized by language
* Immunize.org: Clinical Resources: Adolescent Vaccination ([link removed]) main page
------------------------------------------------------------
Immunize.org updates seven translations of its popular patient handout promoting vaccinations for adults
Immunize.org posted seven new translations of the current version of its popular patient handout, Vaccinations for Adults: You're Never Too Old to Get Vaccinated ([link removed]). This 1-page handout summarizes basic information about recommended adult vaccines in one table.
Updates incorporate the latest recommendations for:
* Adults who may need mpox vaccine
* PCV for all adults age 50 and older
New translations include:
* Spanish ([link removed])
* Arabic ([link removed])
* Chinese-Simplified ([link removed])
* French ([link removed])
* Korean ([link removed])
* Russian ([link removed])
* Vietnamese ([link removed])
Related Links
* Immunize.org: Translations ([link removed]) main page, where you can locate available translations of clinical resources and VISs, organized by language
* Immunize.org: Clinical Resources: Adult Vaccination ([link removed]) main page
------------------------------------------------------------
Immunize.org updates its clinical resource, “Hepatitis A, B, and C: Learn the Differences”
Immunize.org updated its Hepatitis A, B, and C: Learn the Differences ([link removed]) clinical resource. Clarifying updates were made in the treatment sections, including the new CDC link for treatment options for hepatitis C.
[link removed]
Related Links
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
* Immunize.org: Clinical Resources: Adult Vaccination ([link removed]) main page
------------------------------------------------------------
Influenza activity gradually increasing; we are thankful for those who vaccinated our friends and families this holiday season
The 2024–25 U.S. influenza season is underway and now is the time to vaccinate. For week 46, ending November 16, CDC’s Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), shows influenza activity increasing slightly.
RESP-NET
Visit the CDC Respiratory Virus Hospitalization Surveillance Network (RESP-NET) ([link removed]) for weekly reports of hospitalizations due to three vaccine-preventable seasonal respiratory viruses: COVID-19, influenza, and RSV.
Influenza Vaccination Dashboard
CDC's Weekly Flu Vaccination Dashboard ([link removed]) shows that, as of November 9, 2024, 31.2% of pregnant patients had received flu vaccination, compared with 31.8% at that point in 2023. Vaccination coverage during pregnancy decreased between 2019–20 and 2023–24 overall and in all race and ethnicity groups. Vaccination during pregnancy helps protect both mother and infant from the consequences of influenza infection.
CDC recommends everyone age 6 months and older get annual influenza vaccination. Influenza and other vaccines (e.g., COVID-19, RSV) may be given at the same visit, if needed. Infants age 6 months and older may receive influenza and COVID-19 vaccines at the same visit when receiving nirsevimab (Beyfortus, Sanofi).
Identify pharmacies in your area that may offer influenza and COVID-19 vaccines by entering a zip code in the VaccineFinder on Vaccines.gov ([link removed]) or Vacunas.gov ([link removed]).
Related Links
* CDC: Weekly National Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: RESP-NET ([link removed]) main page
* Immunize.org: free clinical resources and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
------------------------------------------------------------
Immunize.org’s Hepatitis B Birth Dose Honor Roll recognizes 586 institutions, including one new honoree
Immunize.org is pleased to welcome one new institution into its Hepatitis B Birth Dose Honor Roll ([link removed]), which now recognizes 586 honorees. The new birthing institution appears below with its reported HepB birth dose coverage rate in parentheses.
* John Peter Smith Hospital, Fort Worth, TX (98%)
Please join us in recognizing these honorees with sustained excellence that qualify for an additional year:
* Danbury Hospital, Danbury, CT (90%) (2 years)
* Jamaica Hospital Medical Center, Jamaica, NY (93%) (2 years)
* Shannon Medical Center, San Angelo, TX (94%) (4 years)
* Sharon Hospital, Sharon, CT (93%) (4 years)
* Bristol Hospital, Bristol, CT (92%) (7 years)
* ChristianaCare Christiana Hospital, Newark, DE (91%) (8 years)
The Honor Roll includes birthing institutions from 45 states, the District of Columbia, Puerto Rico, Guam, Saipan, and our U.S. military hospital in England.
The Honor Roll is a key part of Immunize.org’s initiative urging the nation’s hospitals to Give Birth to the End of Hep B ([link removed]) . Hospitals and birthing centers are recognized for attaining high coverage for HepB vaccine at birth and meeting additional criteria. To learn whether your organization qualifies and to access the application form, please see Hepatitis B Birth Dose Honor Roll online ([link removed](healthcare)).
Honorees receive an 8.5" x 11" color certificate suitable for printing and framing. Their acceptance is announced through Immunize.org’s social media channels and to IZ Express’s readers.
Please visit the Hepatitis B Birth Dose Honor Roll web page that lists these institutions and celebrates their vigorous efforts to protect infants from perinatal hepatitis B transmission.
Related Immunize.org Resources
* Give Birth to the End of Hep B ([link removed]) main page
* Fact sheet: Do You Qualify for the Hepatitis B Birth Dose Honor Roll? If So, Apply Today. ([link removed])
* Handout on Immunize.org’s campaign: Give Birth to the End of Hep B ([link removed])
* Hepatitis B Birth Dose Honor Roll ([link removed](healthcare)) web page
------------------------------------------------------------
"How Effective Is Tdap Vaccination During Pregnancy at Protecting Newborns from Pertussis?” Watch the 2-minute answer, part of the Ask the Experts Video Series on YouTube.
This week, our featured episode from the Ask the Experts Video Series is How Effective Is Tdap Vaccination During Pregnancy at Protecting Newborns from Pertussis? ([link removed]) Tdap given during pregnancy is highly effective at preventing pertussis (whooping cough) in infants. It is, by far, the best way to minimize the risk of pertussis hospitalization during baby’s first months of life.
The 2-minute video is available on our YouTube channel ([link removed]), along with our full collection of quick video answers to popular Ask the Experts ([link removed]) questions.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Pew Research Center: 60% of Americans Say They Probably Won’t Get an Updated COVID-19 Vaccine ([link removed]) (11/19/24)
* Axios: More Kindergartners Are Getting Vaccine Exemptions ([link removed]) (11/18/24)
* KFF: The Public’s Views on Vaccines, Mandates and More ([link removed]) (11/18/24)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Recap: Immunize.org issues updated “Standing Orders for Administering Pneumococcal Vaccines to Adults” incorporating ACIP recommendation for routine vaccination starting at age 50 years
Immunize.org updated Standing Orders for Administering Pneumococcal Vaccines to Adults ([link removed]). The template adheres to the October 2024 recommendations for routine vaccination of adults with a PCV beginning at age 50. It also follows new CDC guidance that eliminates the option for adults with a history of PCV13 (Prevnar 13, Pfizer) and/or PPSV23 (Pneumovax 23, Merck) to follow up with a dose of PPSV23.
------------------------------------------------------------
Recap: Immunize.org updates its “Ask the Experts” web page on pneumococcal vaccines to reflect new adult recommendations
Immunize.org updated the questions and answers in its "Ask the Experts" web page for pneumococcal vaccine ([link removed]). Updates incorporate the changes to adult pneumococcal vaccine recommendations voted on at the October 23–24 ACIP meeting. Questions and answers reflect the new recommendation to lower the age of routine vaccination of adults with a PCV from 65 to 50. The content also incorporates CDC guidance specifying that options for vaccination include one dose of either PCV20 or PCV21 alone, or a series of PCV15 followed by a dose of PPSV23 one year later.
Immunize.org's Ask the Experts ([link removed]) main page leads you to 30 distinct web pages on a variety of topics with more than 1,300 common or challenging questions and answers (Q&As) about vaccines and their administration. Immunize.org's team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane R. Zucker, MD, MPH.
------------------------------------------------------------
Recap: Immunize.org updates two “Questions and Answers” resources, one for polio and one for rabies
Immunize.org updated two of its "Questions and Answers" resources.
* Polio: Questions and Answers ([link removed]): Edits update epidemiology and clarify adult vaccination recommendations and the interpretation of OPV records. A new question addresses the fact that serologic testing for evidence of previous polio vaccination is not available and not recommended.
* Rabies: Questions and Answers ([link removed]): Edits update data on reported animal rabies.
------------------------------------------------------------
Recap: Immunize.org updates content in three clinical resources
Immunize.org is reviewing its clinical resources and web pages to update broken URLs resulting from the recent reorganization of the CDC website. Immunize.org updated URLs on three clinical resources:
* Key Vaccination Resources for Healthcare Professionals ([link removed])
* Vaccinations Are Safe: Explaining Why ([link removed])
* Don't Be Guilty of These Preventable Errors in Vaccine Administration! ([link removed])
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Recap: Immunize.org updates Spanish translations of four popular VISs
Immunize.org posted up-to-date Spanish translations of four VISs:
* COVID-19 Vaccine VIS ([link removed]) (view in English ([link removed]))
* RSV Vaccine VIS ([link removed]) (view in English ([link removed]))
* Typhoid Vaccine VIS ([link removed]) (view in English ([link removed]))
* Yellow Fever Vaccine VIS ([link removed]) (view in English ([link removed]))
To locate VIS translations for a particular vaccine, click on “Vaccines & VISs” at Immunize.org, click on “VISs,” and then select a specific vaccine. Scrolling down the resulting page, you will see the current English VIS (the official federal version), followed by a list of translations of the current English version. If applicable, current translations are followed by a list of any translations of past English versions that are still usable because they are the most recent translations available in those languages. When a patient is given any VIS translation, they should also receive the current VIS in English. Additional tips on using VISs appear at the bottom of the page.
Check the version date of your inventory of VIS translations. Discard translations of previous versions as translations of current versions become available.
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
CDC reports on pediatrician and obstetrician attitudes, practices, and challenges with administering nirsevimab and RSV vaccine
On November 14, CDC released an online report titled Pediatrician and OB/GYN Survey on RSV Immunization ([link removed]). The report explored provider attitudes, practices, and challenges related to giving nirsevimab (Beyfortus, Sanofi) to infants and maternal RSV vaccine (Abrysvo, Pfizer) during pregnancy. The summary appears below.
Among pediatric and obstetrician/gynecologist (OB/GYN) providers, 77.0% of pediatricians had ever offered nirsevimab and 63.0% of OB/GYNs offered respiratory syncytial virus (RSV) vaccine to pregnant patients. Providers were confident in the safety and effectiveness of nirsevimab and maternal RSV vaccine. Primary challenges reported included: 1) parent/caregiver or patient concerns around safety and effectiveness of products; 2) financial burden of purchasing the products; and 3) reimbursement issues.
CDC and healthcare professional organizations have developed a range of resources to support infant RSV immunization. Use the resources below to communicate with parents and patients.
Vaccination/Immunization Guidance
* CDC: RSV Vaccine Guidance for Pregnant People ([link removed])
* CDC: RSV Immunization Guidance for Infants and Young Children ([link removed])
Physician Tools and Guidance
* American College of Obstetricians and Gynecologists: Physician Tools ([link removed])
* CDC: Best Practices for Patient Care | Respiratory Illnesses ([link removed])
* CDC: Talking with Patients About Respiratory Virus Season ([link removed])
* American Academy of Pediatrics (AAP): Nirsevimab Coding & Payment Guidance ([link removed])
* AAP: Nirsevimab Frequently Asked Questions ([link removed])
* AAP: Recommendations for the Prevention of RSV Disease in Infants and Children ([link removed])
* CDC: Infant RSV Prevention At-A-Glance ([link removed])
Tribal Toolkit
* CDC: RSV Tribal Toolkit ([link removed])
Parent/Caregiver Resources
* AAP: RSV: When It's More Than Just a Cold, HealthyChildren.org ([link removed](12%20weeks).)
* CDC: RSV in Infants and Young Children ([link removed])
* CDC: RSV Immunization Chart ([link removed])
Related Link
* CDC: Pediatrician and OB/GYN Survey on RSV Immunization ([link removed])
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Questions about our website? Register for the next Immunize.org Website Office Hours on December 4 at 4:00 p.m. (ET) or December 5 at 12:00 p.m. (ET). Previously recorded sessions available online.
To learn tips and tricks for using our website efficiently, please register for our next set of Website Office Hours on Wednesday, December 4 at 4:00 p.m. (ET) ([link removed]) or Thursday, December 5 at 12:00 p.m. (ET) ([link removed]). The same content will be covered in both sessions.
We will open each 45-minute session with a short, live demonstration on navigating two web sections: the new “Travel Vaccines” section and the “Vaccine Confidence and Addressing Concerns” section. You can submit questions when you register or live on Zoom during the session.
Register today for Immunize.org Website Office Hours (content is the same for both):
* Wednesday, December 4 at 4:00 p.m. (ET) ([link removed])
* Thursday, December 5 at 12:00 p.m. (ET) ([link removed])
To view Immunize.org Website Office Hours sessions, visit Immunize.org’s Webinars & Videos ([link removed]) page. Recent topics include “Vaccines A–Z,” “Clinical Resources,” “Vaccine Information Statements (VIS),” and “Ask the Experts” web sections.
Mark your calendar ([link removed]) for future monthly Immunize.org Website Office Hours. The next pair of sessions will be held in January 2025.
------------------------------------------------------------
Opportunity for students in grades 6 through 12: 2025 Dr. Maurice R. Hilleman Essay Contest is open for submissions
The Vaccine Makers Project ([link removed]), the classroom-based program of the Vaccine Education Center ([link removed]) at Children’s Hospital of Philadelphia, invites submissions for the 2025 Maurice R. Hilleman Essay Contest. Students in grades 6 through 12 in the United States and Canada are encouraged to learn about Dr. Hilleman’s life and accomplishments and submit a 500- to 1,000-word essay by February 6, 2025. This year's writing prompt is "Not everyone will be a prolific scientist like Dr. Hilleman, but all citizens need to understand how science works. Use an example to discuss why this understanding is important given the role of science and technology in society today."
Details and the entry form are available at HillemanFilm.com/contest ([link removed]). First and second place will be awarded in the high school and middle school categories in each country (United States and Canada). Winners will receive $500 (first place) and $250 (second place), a certificate, and recognition at a virtual award event this fall. Please share this information with teachers and eligible students.
Related Links
* The Vaccine Makers Project ([link removed]) website
* VEC: Hilleman Film ([link removed]) website
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer (http:// [link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,788: November 27, 2024
Top Stories
* “Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults—United States, Fall 2024” published in MMWR
* “Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents—National Healthcare Safety Network, United States, November 2024” published in MMWR
* VBI Vaccines recalls remaining doses of PreHevbrio, its HepB vaccine, as part of business closure, not due to vaccine safety or effectiveness
* CDC issues Health Alert Network (HAN) Health Advisory: “First Case of Clade I Mpox Diagnosed in the United States”
* National Influenza Vaccination Week is December 2–6. Encourage vaccination using CDC’s digital media toolkit.
* Immunize.org offers new Spanish translation of the clinical resource, “Record of Vaccine Declination”
* Immunize.org updates Spanish translation of the patient handout, "You're 16 . . . We Recommend These Vaccines for You!"
* Immunize.org updates seven translations of its popular patient handout promoting vaccinations for adults
* Immunize.org updates its clinical resource, “Hepatitis A, B, and C: Learn the Differences”
* Influenza activity gradually increasing; we are thankful for those who vaccinated our friends and families this holiday season
* Immunize.org’s Hepatitis B Birth Dose Honor Roll recognizes 586 institutions, including one new honoree
* "How Effective Is Tdap Vaccination During Pregnancy at Protecting Newborns from Pertussis?” Watch the 2-minute answer, part of the Ask the Experts Video Series on YouTube.
* Vaccines in the news
Immunize.org Website and Clinical Resources
* Recap: Immunize.org issues updated “Standing Orders for Administering Pneumococcal Vaccines to Adults” incorporating ACIP recommendation for routine vaccination starting at age 50 years
* Recap: Immunize.org updates its “Ask the Experts” web page on pneumococcal vaccines to reflect new adult recommendations
* Recap: Immunize.org updates two “Questions and Answers” resources, one for polio and one for rabies
* Recap: Immunize.org updates content in three clinical resources
Vaccine Information Statements
* Recap: Immunize.org updates Spanish translations of four popular VISs
Notable Publications
* CDC reports on pediatrician and obstetrician attitudes, practices, and challenges with administering nirsevimab and RSV vaccine
Upcoming Events
* Virtual: Questions about our website? Register for the next Immunize.org Website Office Hours on December 4 at 4:00 p.m. (ET) or December 5 at 12:00 p.m. (ET). Previously recorded sessions available online.
* Opportunity for students in grades 6 through 12: 2025 Dr. Maurice R. Hilleman Essay Contest is open for submissions
------------------------------------------------------------
Top Stories
------------------------------------------------------------
“Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults—United States, Fall 2024” published in MMWR
CDC published Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults—United States, Fall 2024 ([link removed]) on November 21 in MMWR. Most adults still need to be vaccinated against important respiratory viruses this season. A portion of the summary appears below.
The Advisory Committee on Immunization Practices recommends that all persons aged ≥6 months, including adults aged ≥18 years, receive annual influenza and COVID-19 vaccines, and that all adults aged ≥75 years and those aged 60–74 years at increased risk for severe respiratory syncytial virus (RSV) disease receive 1 dose of RSV vaccine. . . .
By November 9, 2024, an estimated 34.7% and 17.9% of adults aged ≥18 years had received influenza and COVID-19 vaccines, respectively, for the 2024–25 season; 39.7% of adults aged ≥75 years and 31.6% of adults aged 60–74 years at increased risk for severe RSV disease had ever received RSV vaccine. Many unvaccinated adults reported intent to get vaccinated. . . .
Health care providers and immunization programs still have time to expand outreach and promote vaccination activities to increase coverage in preparation for the height of the respiratory virus season.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
“Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents—National Healthcare Safety Network, United States, November 2024” published in MMWR
CDC published Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents—National Healthcare Safety Network, United States, November 2024 ([link removed]) on November 21 in MMWR. A portion of the summary appears below.
Nursing home residents are at increased risk for severe COVID-19, influenza, and respiratory syncytial virus (RSV) illness. Vaccination reduces risk for severe outcomes from these vaccine-preventable respiratory diseases. . . .
As of November 10, 2024, 30% of nursing home residents had received a 2024–2025 COVID-19 vaccine. Among residents at nursing home facilities that elected to report vaccination against influenza (59% of facilities) and RSV (52% of facilities), 58% had received influenza vaccination, and only 18% had received RSV vaccination. . . .
Addressing low vaccination coverage against COVID-19, influenza, and RSV is a priority to protect residents susceptible to severe outcomes of respiratory illnesses.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
------------------------------------------------------------
VBI Vaccines recalls remaining doses of PreHevbrio, its HepB vaccine, as part of business closure, not due to vaccine safety or effectiveness
VBI Vaccines, the manufacturer of the PreHevbrio brand of HepB vaccine, declared bankruptcy and is ending business operations. PreHevbrio is no longer being distributed. Customers with the product are asked to destroy or return remaining doses. The recall is not related to vaccine safety or quality. All properly administered doses of PreHevbrio are valid HepB vaccinations and do not need to be repeated.
If you have PreHevbrio or have questions about it, visit www.prehevbrio.com for additional information and guidance.
Adults with an incomplete PreHevbrio vaccination series may complete their series with any of the three FDA-licensed HepB vaccines (Heplisav-B, Dynavax; Engerix-B, GSK; Recombivax-HB, Merck). For a guide to completing a mixed-product vaccination series, see the table in the following Ask the Experts HepB question:
* Can You Show the Options of How to Complete Adult Hepatitis B Vaccination with Different Vaccine Products? ([link removed])
Related Links
* VBI Vaccines: PreHevbrio Vaccine ([link removed]) web page
* Immunize.org: Ask the Experts: Hepatitis B ([link removed]) web page
------------------------------------------------------------
CDC issues Health Alert Network (HAN) Health Advisory: “First Case of Clade I Mpox Diagnosed in the United States”
On November 18, CDC issued a Health Alert Network (HAN) ([link removed]) Health Advisory: First Case of Clade I Mpox Diagnosed in the United States ([link removed]). A portion of the summary of the HAN appears below.
On November 15, 2024, the California Department of Public Health (CDPH) confirmed the first reported case of clade I mpox in the United States. [Clade IIb, a generally milder strain of mpox, was introduced to the United States in 2022 and is the cause of U.S. outbreaks since that time.] This individual had recently traveled to areas experiencing clade I monkeypox virus (MPXV) transmission and sought medical care for mpox symptoms in the United States. Consistent with other recent clade I mpox cases, the patient has relatively mild illness and is recovering. CDC and the local and state health departments are investigating potential contacts; no additional cases in the United States have been detected as of November 18, 2024. The risk of clade I mpox to the public in the United States remains low.
Related Links
* CDC: Interim Clinical Considerations for Use of Jynneos Vaccine for Mpox Prevention in the United States ([link removed])
* Immunize.org: Vaccines A–Z: Mpox ([link removed]) main page
* Immunize.org: Mpox VIS ([link removed]) and available translations
------------------------------------------------------------
National Influenza Vaccination Week is December 2–6. Encourage vaccination using CDC’s digital media toolkit.
The majority of Americans are not prepared for the coming seasonal influenza epidemic. National Influenza Vaccination Week ([link removed]) (NIVW), observed December 2–6 this year, highlights the value of influenza vaccination in December and beyond. First organized by CDC in 2005, NIVW is a great time to post and share reminder messages and vaccinate all those who are not yet protected. Get the word out using CDC's 2024 NIVW Digital Media Toolkit ([link removed]), which include the following assets.
* Sample Newsletter Text: include CDC’s sample text in your email newsletter or other communications
* Patient Reminder Messages: remind patients by sharing key messages through your patient portal or other reminders
* Social Media Messages: use CDC’s suggested X, Facebook, and Instagram graphics and text to spread the word; schedule content to remind your networks about the importance of flu vaccination throughout the week
Use #FightFlu and #NIVW to join the conversation all week.
------------------------------------------------------------
Immunize.org offers new Spanish translation of the clinical resource, “Record of Vaccine Declination”
At the request of a vaccinating nurse at a recent conference, Immunize.org now offers a Spanish translation ([link removed]) of its valuable clinical resource, Record of Vaccine Declination ([link removed]). This form helps vaccination providers document that parents declined vaccination after receiving information about the potential consequences of their choices. Many providers use it to help parents understand that vaccine refusal is an active decision to accept the risks of remaining vulnerable to a preventable disease.
The translation incorporates RSV preventive antibody (nirsevimab, Beyfortus, Sanofi) among immunizing products that parents could decline. The reverse side provides information about the value of documenting declination in the medical record, along with useful references. This section now provides more recent examples of the consequences of not vaccinating, as well as links to resources from the American Academy of Pediatrics and other organizations.
* Record of Vaccine Declination ([link removed]) (view in English ([link removed]) )
Related Links
* Immunize.org: Clinical Resources: Documenting Vaccination ([link removed]) main page
* Immunize.org: Translations ([link removed]) main page, where you can locate available translations of clinical resources and VISs, organized by language
------------------------------------------------------------
Immunize.org updates Spanish translation of the patient handout, "You're 16 . . . We Recommend These Vaccines for You!"
Immunize.org recently updated the Spanish translation ([link removed]) of its patient handout, coproduced with the Society for Adolescent Health and Medicine, You're 16 . . . We Recommend These Vaccines for You! ([link removed]) The handout includes COVID-19 as a routinely recommended vaccine and a footnote about RSV vaccine during pregnancy. Vaccines normally administered to preteens (which may be needed by teens who are not up to date) are now grouped in a separate table.
Related Links
* Immunize.org: Translations ([link removed]) main page, where you can locate available translations of clinical resources and VISs, organized by language
* Immunize.org: Clinical Resources: Adolescent Vaccination ([link removed]) main page
------------------------------------------------------------
Immunize.org updates seven translations of its popular patient handout promoting vaccinations for adults
Immunize.org posted seven new translations of the current version of its popular patient handout, Vaccinations for Adults: You're Never Too Old to Get Vaccinated ([link removed]). This 1-page handout summarizes basic information about recommended adult vaccines in one table.
Updates incorporate the latest recommendations for:
* Adults who may need mpox vaccine
* PCV for all adults age 50 and older
New translations include:
* Spanish ([link removed])
* Arabic ([link removed])
* Chinese-Simplified ([link removed])
* French ([link removed])
* Korean ([link removed])
* Russian ([link removed])
* Vietnamese ([link removed])
Related Links
* Immunize.org: Translations ([link removed]) main page, where you can locate available translations of clinical resources and VISs, organized by language
* Immunize.org: Clinical Resources: Adult Vaccination ([link removed]) main page
------------------------------------------------------------
Immunize.org updates its clinical resource, “Hepatitis A, B, and C: Learn the Differences”
Immunize.org updated its Hepatitis A, B, and C: Learn the Differences ([link removed]) clinical resource. Clarifying updates were made in the treatment sections, including the new CDC link for treatment options for hepatitis C.
[link removed]
Related Links
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
* Immunize.org: Clinical Resources: Adult Vaccination ([link removed]) main page
------------------------------------------------------------
Influenza activity gradually increasing; we are thankful for those who vaccinated our friends and families this holiday season
The 2024–25 U.S. influenza season is underway and now is the time to vaccinate. For week 46, ending November 16, CDC’s Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), shows influenza activity increasing slightly.
RESP-NET
Visit the CDC Respiratory Virus Hospitalization Surveillance Network (RESP-NET) ([link removed]) for weekly reports of hospitalizations due to three vaccine-preventable seasonal respiratory viruses: COVID-19, influenza, and RSV.
Influenza Vaccination Dashboard
CDC's Weekly Flu Vaccination Dashboard ([link removed]) shows that, as of November 9, 2024, 31.2% of pregnant patients had received flu vaccination, compared with 31.8% at that point in 2023. Vaccination coverage during pregnancy decreased between 2019–20 and 2023–24 overall and in all race and ethnicity groups. Vaccination during pregnancy helps protect both mother and infant from the consequences of influenza infection.
CDC recommends everyone age 6 months and older get annual influenza vaccination. Influenza and other vaccines (e.g., COVID-19, RSV) may be given at the same visit, if needed. Infants age 6 months and older may receive influenza and COVID-19 vaccines at the same visit when receiving nirsevimab (Beyfortus, Sanofi).
Identify pharmacies in your area that may offer influenza and COVID-19 vaccines by entering a zip code in the VaccineFinder on Vaccines.gov ([link removed]) or Vacunas.gov ([link removed]).
Related Links
* CDC: Weekly National Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: RESP-NET ([link removed]) main page
* Immunize.org: free clinical resources and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
------------------------------------------------------------
Immunize.org’s Hepatitis B Birth Dose Honor Roll recognizes 586 institutions, including one new honoree
Immunize.org is pleased to welcome one new institution into its Hepatitis B Birth Dose Honor Roll ([link removed]), which now recognizes 586 honorees. The new birthing institution appears below with its reported HepB birth dose coverage rate in parentheses.
* John Peter Smith Hospital, Fort Worth, TX (98%)
Please join us in recognizing these honorees with sustained excellence that qualify for an additional year:
* Danbury Hospital, Danbury, CT (90%) (2 years)
* Jamaica Hospital Medical Center, Jamaica, NY (93%) (2 years)
* Shannon Medical Center, San Angelo, TX (94%) (4 years)
* Sharon Hospital, Sharon, CT (93%) (4 years)
* Bristol Hospital, Bristol, CT (92%) (7 years)
* ChristianaCare Christiana Hospital, Newark, DE (91%) (8 years)
The Honor Roll includes birthing institutions from 45 states, the District of Columbia, Puerto Rico, Guam, Saipan, and our U.S. military hospital in England.
The Honor Roll is a key part of Immunize.org’s initiative urging the nation’s hospitals to Give Birth to the End of Hep B ([link removed]) . Hospitals and birthing centers are recognized for attaining high coverage for HepB vaccine at birth and meeting additional criteria. To learn whether your organization qualifies and to access the application form, please see Hepatitis B Birth Dose Honor Roll online ([link removed](healthcare)).
Honorees receive an 8.5" x 11" color certificate suitable for printing and framing. Their acceptance is announced through Immunize.org’s social media channels and to IZ Express’s readers.
Please visit the Hepatitis B Birth Dose Honor Roll web page that lists these institutions and celebrates their vigorous efforts to protect infants from perinatal hepatitis B transmission.
Related Immunize.org Resources
* Give Birth to the End of Hep B ([link removed]) main page
* Fact sheet: Do You Qualify for the Hepatitis B Birth Dose Honor Roll? If So, Apply Today. ([link removed])
* Handout on Immunize.org’s campaign: Give Birth to the End of Hep B ([link removed])
* Hepatitis B Birth Dose Honor Roll ([link removed](healthcare)) web page
------------------------------------------------------------
"How Effective Is Tdap Vaccination During Pregnancy at Protecting Newborns from Pertussis?” Watch the 2-minute answer, part of the Ask the Experts Video Series on YouTube.
This week, our featured episode from the Ask the Experts Video Series is How Effective Is Tdap Vaccination During Pregnancy at Protecting Newborns from Pertussis? ([link removed]) Tdap given during pregnancy is highly effective at preventing pertussis (whooping cough) in infants. It is, by far, the best way to minimize the risk of pertussis hospitalization during baby’s first months of life.
The 2-minute video is available on our YouTube channel ([link removed]), along with our full collection of quick video answers to popular Ask the Experts ([link removed]) questions.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Pew Research Center: 60% of Americans Say They Probably Won’t Get an Updated COVID-19 Vaccine ([link removed]) (11/19/24)
* Axios: More Kindergartners Are Getting Vaccine Exemptions ([link removed]) (11/18/24)
* KFF: The Public’s Views on Vaccines, Mandates and More ([link removed]) (11/18/24)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Recap: Immunize.org issues updated “Standing Orders for Administering Pneumococcal Vaccines to Adults” incorporating ACIP recommendation for routine vaccination starting at age 50 years
Immunize.org updated Standing Orders for Administering Pneumococcal Vaccines to Adults ([link removed]). The template adheres to the October 2024 recommendations for routine vaccination of adults with a PCV beginning at age 50. It also follows new CDC guidance that eliminates the option for adults with a history of PCV13 (Prevnar 13, Pfizer) and/or PPSV23 (Pneumovax 23, Merck) to follow up with a dose of PPSV23.
------------------------------------------------------------
Recap: Immunize.org updates its “Ask the Experts” web page on pneumococcal vaccines to reflect new adult recommendations
Immunize.org updated the questions and answers in its "Ask the Experts" web page for pneumococcal vaccine ([link removed]). Updates incorporate the changes to adult pneumococcal vaccine recommendations voted on at the October 23–24 ACIP meeting. Questions and answers reflect the new recommendation to lower the age of routine vaccination of adults with a PCV from 65 to 50. The content also incorporates CDC guidance specifying that options for vaccination include one dose of either PCV20 or PCV21 alone, or a series of PCV15 followed by a dose of PPSV23 one year later.
Immunize.org's Ask the Experts ([link removed]) main page leads you to 30 distinct web pages on a variety of topics with more than 1,300 common or challenging questions and answers (Q&As) about vaccines and their administration. Immunize.org's team of experts includes Kelly L. Moore, MD, MPH (team lead); Carolyn B. Bridges, MD, FACP; Iyabode Beysolow, MD, MPH; and Jane R. Zucker, MD, MPH.
------------------------------------------------------------
Recap: Immunize.org updates two “Questions and Answers” resources, one for polio and one for rabies
Immunize.org updated two of its "Questions and Answers" resources.
* Polio: Questions and Answers ([link removed]): Edits update epidemiology and clarify adult vaccination recommendations and the interpretation of OPV records. A new question addresses the fact that serologic testing for evidence of previous polio vaccination is not available and not recommended.
* Rabies: Questions and Answers ([link removed]): Edits update data on reported animal rabies.
------------------------------------------------------------
Recap: Immunize.org updates content in three clinical resources
Immunize.org is reviewing its clinical resources and web pages to update broken URLs resulting from the recent reorganization of the CDC website. Immunize.org updated URLs on three clinical resources:
* Key Vaccination Resources for Healthcare Professionals ([link removed])
* Vaccinations Are Safe: Explaining Why ([link removed])
* Don't Be Guilty of These Preventable Errors in Vaccine Administration! ([link removed])
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Recap: Immunize.org updates Spanish translations of four popular VISs
Immunize.org posted up-to-date Spanish translations of four VISs:
* COVID-19 Vaccine VIS ([link removed]) (view in English ([link removed]))
* RSV Vaccine VIS ([link removed]) (view in English ([link removed]))
* Typhoid Vaccine VIS ([link removed]) (view in English ([link removed]))
* Yellow Fever Vaccine VIS ([link removed]) (view in English ([link removed]))
To locate VIS translations for a particular vaccine, click on “Vaccines & VISs” at Immunize.org, click on “VISs,” and then select a specific vaccine. Scrolling down the resulting page, you will see the current English VIS (the official federal version), followed by a list of translations of the current English version. If applicable, current translations are followed by a list of any translations of past English versions that are still usable because they are the most recent translations available in those languages. When a patient is given any VIS translation, they should also receive the current VIS in English. Additional tips on using VISs appear at the bottom of the page.
Check the version date of your inventory of VIS translations. Discard translations of previous versions as translations of current versions become available.
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
CDC reports on pediatrician and obstetrician attitudes, practices, and challenges with administering nirsevimab and RSV vaccine
On November 14, CDC released an online report titled Pediatrician and OB/GYN Survey on RSV Immunization ([link removed]). The report explored provider attitudes, practices, and challenges related to giving nirsevimab (Beyfortus, Sanofi) to infants and maternal RSV vaccine (Abrysvo, Pfizer) during pregnancy. The summary appears below.
Among pediatric and obstetrician/gynecologist (OB/GYN) providers, 77.0% of pediatricians had ever offered nirsevimab and 63.0% of OB/GYNs offered respiratory syncytial virus (RSV) vaccine to pregnant patients. Providers were confident in the safety and effectiveness of nirsevimab and maternal RSV vaccine. Primary challenges reported included: 1) parent/caregiver or patient concerns around safety and effectiveness of products; 2) financial burden of purchasing the products; and 3) reimbursement issues.
CDC and healthcare professional organizations have developed a range of resources to support infant RSV immunization. Use the resources below to communicate with parents and patients.
Vaccination/Immunization Guidance
* CDC: RSV Vaccine Guidance for Pregnant People ([link removed])
* CDC: RSV Immunization Guidance for Infants and Young Children ([link removed])
Physician Tools and Guidance
* American College of Obstetricians and Gynecologists: Physician Tools ([link removed])
* CDC: Best Practices for Patient Care | Respiratory Illnesses ([link removed])
* CDC: Talking with Patients About Respiratory Virus Season ([link removed])
* American Academy of Pediatrics (AAP): Nirsevimab Coding & Payment Guidance ([link removed])
* AAP: Nirsevimab Frequently Asked Questions ([link removed])
* AAP: Recommendations for the Prevention of RSV Disease in Infants and Children ([link removed])
* CDC: Infant RSV Prevention At-A-Glance ([link removed])
Tribal Toolkit
* CDC: RSV Tribal Toolkit ([link removed])
Parent/Caregiver Resources
* AAP: RSV: When It's More Than Just a Cold, HealthyChildren.org ([link removed](12%20weeks).)
* CDC: RSV in Infants and Young Children ([link removed])
* CDC: RSV Immunization Chart ([link removed])
Related Link
* CDC: Pediatrician and OB/GYN Survey on RSV Immunization ([link removed])
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Questions about our website? Register for the next Immunize.org Website Office Hours on December 4 at 4:00 p.m. (ET) or December 5 at 12:00 p.m. (ET). Previously recorded sessions available online.
To learn tips and tricks for using our website efficiently, please register for our next set of Website Office Hours on Wednesday, December 4 at 4:00 p.m. (ET) ([link removed]) or Thursday, December 5 at 12:00 p.m. (ET) ([link removed]). The same content will be covered in both sessions.
We will open each 45-minute session with a short, live demonstration on navigating two web sections: the new “Travel Vaccines” section and the “Vaccine Confidence and Addressing Concerns” section. You can submit questions when you register or live on Zoom during the session.
Register today for Immunize.org Website Office Hours (content is the same for both):
* Wednesday, December 4 at 4:00 p.m. (ET) ([link removed])
* Thursday, December 5 at 12:00 p.m. (ET) ([link removed])
To view Immunize.org Website Office Hours sessions, visit Immunize.org’s Webinars & Videos ([link removed]) page. Recent topics include “Vaccines A–Z,” “Clinical Resources,” “Vaccine Information Statements (VIS),” and “Ask the Experts” web sections.
Mark your calendar ([link removed]) for future monthly Immunize.org Website Office Hours. The next pair of sessions will be held in January 2025.
------------------------------------------------------------
Opportunity for students in grades 6 through 12: 2025 Dr. Maurice R. Hilleman Essay Contest is open for submissions
The Vaccine Makers Project ([link removed]), the classroom-based program of the Vaccine Education Center ([link removed]) at Children’s Hospital of Philadelphia, invites submissions for the 2025 Maurice R. Hilleman Essay Contest. Students in grades 6 through 12 in the United States and Canada are encouraged to learn about Dr. Hilleman’s life and accomplishments and submit a 500- to 1,000-word essay by February 6, 2025. This year's writing prompt is "Not everyone will be a prolific scientist like Dr. Hilleman, but all citizens need to understand how science works. Use an example to discuss why this understanding is important given the role of science and technology in society today."
Details and the entry form are available at HillemanFilm.com/contest ([link removed]). First and second place will be awarded in the high school and middle school categories in each country (United States and Canada). Winners will receive $500 (first place) and $250 (second place), a certificate, and recognition at a virtual award event this fall. Please share this information with teachers and eligible students.
Related Links
* The Vaccine Makers Project ([link removed]) website
* VEC: Hilleman Film ([link removed]) website
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer (http:// [link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp